Frazier Life Sciences Public Fund, L.P. - 05 May 2026 SCHEDULE 13G Report for VALNEVA SE Ordinary Shares, nominal value EURO0.15 per share, represented by American Depository Shares (VALN)

Filing manager
Frazier Life Sciences Public Fund, L.P.
Reporting owner
Frazier Life Sciences Public Fund, L.P.
Security
VALNEVA SE Ordinary Shares, nominal value EURO0.15 per share, represented by American Depository Shares
Beneficially owned shares
6,879,516 shares
Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13G

Passive or exempt beneficial ownership filing.

Ownership

3.6%

Beneficial ownership of this reported class.

Shares

6,879,516 shares

Shares beneficially owned as disclosed.

Event date

05 May 2026

Date tied to the ownership event or amendment.

Accepted by SEC

12 May 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership
3.6%
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
VALN
Shares outstanding
191,097,667 shares
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
SCHEDULE 13G
Accepted by SEC
12 May 2026, 16:32:30 UTC
Event date
05 May 2026
Source filing
View source filing

Key filing fact

Frazier Life Sciences Public Fund, L.P. disclosed 3.6% ownership in VALNEVA SE Ordinary Shares, nominal value EURO0.15 per share, represented by American Depository Shares (VALN) on 05 May 2026.

Key facts

  • Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G for VALNEVA SE Ordinary Shares, nominal value EURO0.15 per share, represented by American Depository Shares (VALN).
  • Disclosed ownership: 3.6%.
  • Date of event: 05 May 2026.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 12 May 2026, 16:32.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (14)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
Frazier Life Sciences Public Fund, L.P. 3.6% 6,879,516 0 6,879,516 /s/ Jennifer Martin By Jennifer, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
FHMLSP, L.P. 3.6% 6,879,516 0 6,879,516 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
FHMLSP, L.L.C. 3.6% 6,879,516 0 6,879,516 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C.
Frazier Life Sciences X, L.P. 0.1% 115,500 0 115,500 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
FHMLS X, L.P. 0.1% 115,500 0 115,500 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
FHMLS X, L.L.C. 0.1% 115,500 0 115,500 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. 0.2% 337,989 0 337,989 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
FHMLS XI, L.P. 0.2% 337,989 0 337,989 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
FHMLS XI, L.L.C. 0.2% 337,989 0 337,989 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. 0.5% 918,572 0 918,572 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
FHMLS XII, L.P. 0.5% 918,572 0 918,572 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
FHMLS XII, L.L.C. 0.5% 918,572 0 918,572 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C.
James N. Topper 0.1% 115,500 0 115,500 /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Patrick J. Heron 0.1% 115,500 0 115,500 /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .